AAAditya Umesh Arvindekar

Aditya Umesh Arvindekar

*This is an algorithmically generated author record based on publicly available information.

Aditya Umesh Arvindekar has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Kirti S. Laddha

    Medicinal Natural Products Research Laboratory, Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai, India

    2 shared publications
  • Snehal Arvindekar

    Department of Pharmaceutical Chemistry, Bharati Vidyapeeth College of Pharmacy, Kolhapur, India

    2 shared publications
  • Suraj Narayan Mali

    Department of Pharmaceutical Chemistry, School of Pharmacy, D.Y. Patil University (Deemed to be University),Nerul, Navi Mumbai 400706, India

    2 shared publications
  • Aarti Varne

    Department of Pharmaceutical Chemistry, Anandi College of Pharmacy, Kolhapur, India

    1 shared publication
  • Abhishek Malave

    Department of Pharmaceutical Chemistry, Bharati Vidyapeeth College of Pharmacy, Kolhapur, India

    1 shared publication
  • Aishwarya Patil

    Department of Pharmaceutical Chemistry, Bharati Vidyapeeth College of Pharmacy, Kolhapur, Maharashtra, India

    1 shared publication

Latest Publications

  • Identifying the Potential of Herbal Phytochemicals Combination for Pancreatic Lipase Inhibition: Insights into Anti-Obesity Potential

    by Snehal Arvindekar, Abhishek Malave, Rohit Akolkar, Asha Jadhav, Suraj Mali, Aarti Varne, Aditya Arvindekar

  • Open Access

    Computational studies and structural insights for discovery of potential natural aromatase modulators for hormone-dependent breast cancer

    by Snehal Aditya Arvindekar, Sanket Rathod, Prafulla Balkrishna Choudhari, Pradnya Kiran Mane, Aditya Umesh Arvindekar, Suraj Narayan Mali, Bapu Thorat

    Introduction: The aromatase enzyme plays an important role in the progress of hormone-dependent breast cancer, especially in estrogen receptor-positive (ER+) breast cancers. In case of postmenopausal women, the aromatization of androstenedione to estrone in adipose tissue is the most important source of estrogen. Generally 60%-75% of pre- and post-menopausal women suffer from estrogen-dependent breast cancer, and thus suppressing estrogen has been recognized to be a successful therapy. Hence, to limit the stimulation of estrogen, aromatase inhibitors (AIs) are used in the second-line treatment of breast cancer. Methods: The present computational study employed an in silico approach in the identification of natural actives targeting the aromatase enzyme from a structurally diverse set of natural products. Molecular docking, QSAR studies and pharmacophore modeling were carried out using the VLife Molecular Design Suite (version 4.6). The stability of the compounds was confirmed by molecular dynamics. Results: From molecular docking and analysis of interactions with the amino acid residues of the binding cavity, it was found that the amino acid residues interacting with the non-steroidal inhibitors exhibited π-stacking interactions with PHE134, PHE 221, and TRP 224, while the steroidal drug exemestane lacked π-stacking interactions. QSAR studies were performed using the flavonoid compounds, in order to identify the structural functionalities needed to improve the anti-breast cancer activity. Molecular dynamics of the screened hits confirmed the stability of compounds with the target in the binding cavity. Moreover, pharmacophore modelling presented the pharmacophoric features of the selected scaffolds for aromatase inhibitory activity. Conclusion: The results presented 23 hit compounds that can be developed as anti-breast cancer modulating agents in the near future. Additionally, anthraquinone compounds with minor structural modification can also serve to be potential aromatase inhibitors. The in silico protocol utilised can be useful in the drug discovery process for development of new leads from structurally diverse set of natural products that are comparable to the drugs used clinically in breast cancer therapy.


  • Molecular docking, QSAR, pharmacophore modeling, and dynamics studies of some chromone derivatives for the discovery of anti-breast cancer agents against hormone-dependent breast cancer

    by Snehal A. Arvindekar, Suraj Mohole, Aishwarya Patil, Pradnya Mane, Aditya Arvindekar, Suraj N. Mali, Bapu Thorat, Ravi Rawat, Shilpa Sharma

    In search of new anti-breast cancer agents, the present study envisaged the design and synthesis of a series of benzopyran-chalcones. All the synthesized compounds were assayed for their in-vitro anticancer activity against ER + MCF-7 and triple-negative MDA-MB-231 breast cancer cell lines using SRB assay. The synthesized compounds were found active against ER + MCF-7 cell lines. Based on the in-vitro data, in-silico analysis was performed using hormone-dependent breast cancer targets such as hER-α and aromatase because the compounds showed activity against MCF-7 cells and none was active against MDA-MB-231. The in-silico results supported the in-vitro anticancer activity suggesting the affinity of compounds toward hormone-dependant breast cancer. Compounds 4A1 to 4A3 were found to be most cytotoxic to MCF-7 cells with IC50 values of 31.87, 22.95, and 20.34 μg/ml, respectively (Doxorubicin IC50: <10 μg/ml). In addition, they showed the interactions with the amino acid residues of a binding cavity of an hER-α. Furthermore, quantitative structure-activity relationship (QSAR) studies were performed to reveal the vital structural features required for anticancer activity against breast cancer. Molecular dynamic simulation studies of hER-α and 4A3 in comparison with the raloxifene complex ensure the appropriate refinement of compounds in the dynamic system. Additionally, a generated pharmacophore model explored the essential pharmacophoric features of the synthesized scaffolds with respect to clinically used drug molecules for optimal hormone-dependant anti-breast cancer activity. Communicated by Ramaswamy H. Sarma Communicated by Ramaswamy H. Sarma


  • Assessment of conventional and novel extraction techniques on extraction efficiency of five anthraquinones from Rheum emodi

    by Aditya U. Arvindekar, Galvina R. Pereira, Kirti S. Laddha

    Rheum emodi is principally known to consist 1,8-dihydroxyanthraquinones (DHAQs) that find immense use in the chemical, pharmaceutical, cosmetic industries and in herbal medication and food sector. The aim of this study was to compare non-conventional and classical methods for extraction of anthraquinones from R. emodi. Optimisation of the extraction parameters for various methods was done and their extraction efficiency was evaluated. In preliminary screening experiments, choice of solvent and solid : solvent ratio was optimised. Comparison of extraction efficiency for classical methods like maceration, heat-reflux, soxhletion and non-conventional methods like ultra-sonication and sublimation was done for five DHAQs - aloe emodin, rhein, emodin, chrysophanol and physcion using HPLC-UV and fluorescence detection in native and acid hydrolysed samples. It was observed that ethanol was the best solvent for extraction of anthraquinones with a solid : solvent ratio of 1:20. A prior acid hydrolysis led to significant increase in anthraquinone extraction. Among the extraction methods heat reflux for 45 min was the most prominent extraction method with highest recovery of the DHAQs. In ultrasonic assisted extraction, an increase in the anthraquinone extraction was seen till 45 min after which the concentration declined. A novel, solvent-free, green and selective method of extraction by sublimation was found to be effective for extraction of anthraquinones.


  • Estimation of Anthraquinones and their Glycosides from Rhizomes of Rheum emodi

    by Aditya U. Arvindekar, Kirti S. Laddha

    Background: Rheum emodi an Indian variety of the Chinese Rhubarb plays a vital role in traditional Chinese and Indian forms of medicine. The plant majorly consists of pharmacologically and therapeutically significant free 1,8-dihydroxy- anthraquinones and their glycosides. Objective: The present work focuses on estimation of the free anthraquinones and their glycosides from Indian Rhubarb (Rheum emodi) viz. emodin, physcion and chrysophanol by an HPLC method using fluorescence detection. Materials and Methods: The anthraquinone aglycones were extracted from the crude drug by treatment with aqueous alkali, subsequent acidification and partitioning using an organic solvent. The glycosides present in the plant material were first subjected to hydrolysis with acid and then treated in the same manner as that of parent aglycones, and both samples were estimated for their quinone content. Results: The total quinone content prior to and after hydrolysis was found to be 1.91% and 4.52% respectively. The specific aglycone content for emodin, chrysophanol and physcion were analyzed by HPLC and were found to be 0.9%, 0.76% and 0.25% respectively in native form while their respective glycosides were found to be 0.6%, 1.52% and 0.25%. Conclusion: The work presents a simple and efficient method for estimation of anthraquinone glycosides, besides the acid hydrolysis of glycosides can lead to enriched source of anthraquinones from R. emodi, which can be exploited at industrial level for commercial maximization of the pharmacologically important quinones.